- cafead May 14, 2020 at 10:52: AM
via Legend Biotech is hoping it can ride the biotech IPO wave and take in a cool $100 million for its cell therapy work.
The Chinese CAR-T player plans to list its stock on the Nasdaq under the ticker "LEGN" to fund the advance of a pipeline spearheaded by Johnson & Johnson-partnered anti-BCMA therapy JNJ-4528, which is in early- to midstage trials.
article source
The Chinese CAR-T player plans to list its stock on the Nasdaq under the ticker "LEGN" to fund the advance of a pipeline spearheaded by Johnson & Johnson-partnered anti-BCMA therapy JNJ-4528, which is in early- to midstage trials.
article source